Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Current Microbiology|September 22, 2021
Characterization of Mercury-Resistant Rhizobacteria for Plant Growth Promotion: An In Vitro and In Silico ApproachAatif Amin, Muhammad Naveed, Umair Munawar, et al.
Scientific Reports|December 4, 2019
Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line modelUmair Munawar, Markus Roth, Santiago Barrio, et al.
Science Advances|February 4, 2026
Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptorsPatrick Eiring, Maximilian J Steinhardt, Nele Bauer, et al.
Leukemia & Lymphoma|July 8, 2022
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agentsAnna Bögelein, Antje Stolzenburg, Patrick Eiring, et al.
Molecular & Cellular Proteomics : MCP|June 26, 2026
Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell linesChien-Yun Lee, Seungbin Han, Larissa Haertle, et al.
The Oncologist|February 12, 2020
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System InvolvementMatteo Claudio Da Vià, Antonio Giovanni Solimando, Andoni Garitano-Trojaola, et al.
Haematologica|April 4, 2024
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Hemasphere|January 24, 2025
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple MyelomaXiang Zhou, Annika Hofmann, Benedict Engel, et al.
Experimental Hematology & Oncology|December 24, 2025
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53Klara Acs, Juho J Miettinen, Philipp Sergeev, et al.
Haematologica|February 2, 2023
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complexXiang Zhou, Andrej Besse, Jessica Peter, et al.
Pageof 3